ASAP Act
The source supplies the latest action, but no lifecycle stage.
Latest action (16 Sep 2026): Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 0.
What this bill does
H.R. 6130, also known as the ASAP Act, would amend the Social Security Act to allow Medicare to cover certain blood-based screening tests for Alzheimer's disease and related dementias. These tests would be for the pre-symptomatic and early stages of these conditions and would need to be cleared or approved by the Food and Drug Administration. The bill specifies that these tests can include genomic sequencing blood tests or other equivalent tests that the Secretary of Health and Human Services determines to be appropriate.
This bill would primarily affect individuals enrolled in Medicare by potentially expanding their access to early detection screenings for dementia. It also impacts healthcare providers who would offer these services and the manufacturers of approved diagnostic tests. The legislation aims to provide coverage for these tests starting January 1, 2028.
As of September 16, 2026, H.R. 6130 has been ordered to be reported by the House of Representatives with a vote of 40-0. This means the bill has passed through a committee and is now ready to be considered further by the full House. If passed by the House, it would then proceed to the Senate for consideration.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Alzheimer's Screening and Prevention Act of 2025 or the ASAP Act
This bill provides for Medicare coverage of blood tests to screen for the early stages of Alzheimer’s disease or related dementias. Specifically, the bill provides for coverage of genomic sequencing blood or blood product tests, or other equivalent tests, that are approved by the Food and Drug Administration.
Timeline
16 Sep 2026
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 0.
Common questions
- What does H.R. 6130 do?
- H.R. 6130, also known as the ASAP Act, would amend the Social Security Act to allow Medicare to cover certain blood-based screening tests for Alzheimer's disease and related dementias. These tests would be for the pre-symptomatic and early stages of these conditions and would need to be cleared or approved by the Food and Drug Administration. The bill specifies that these tests can include genomic sequencing blood tests or other equivalent tests that the Secretary of Health and Human Services determines to be appropriate. This bill would primarily affect individuals enrolled in Medicare by potentially expanding their access to early detection screenings for dementia. It also impacts healthcare providers who would offer these services and the manufacturers of approved diagnostic tests. The legislation aims to provide coverage for these tests starting January 1, 2028. As of September 16, 2026, H.R. 6130 has been ordered to be reported by the House of Representatives with a vote of 40-0. This means the bill has passed through a committee and is now ready to be considered further by the full House. If passed by the House, it would then proceed to the Senate for consideration.
- Has H.R. 6130 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 6130. Check the latest action and official source below.
- Who sponsored H.R. 6130?
- H.R. 6130 was sponsored by Rep. Buchanan, Vern [R-FL-16] (R-FL), with 235 cosponsors.
- What's the latest action on H.R. 6130?
- Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 0. (16 Sep 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
340B Rebate Model Delay Act
Lower Premiums, Faster Payments Act
More bills from Rep. Buchanan, Vern [R-FL-16]
AI Tax Integrity Act of 2026
AI Fraud Accountability Act
DETECT Act of 2025
American Medical Innovation and Investment Act of 2024
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.